Rheumocam

1 x 15 ml

Oral Suspension

Active substance

Meloxicam : 1,5 mg/ml

ATC code

QM01AC06 Meloxicam

QM01AC Oxicams

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Dogs.

Indications

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

Dose to be administered and administration route

Oral use.

Shake well before use.

To be administered mixed with food.

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

To ensure a correct dosage, body weight should be determined as accurately as possible.

The use of suitably calibrated measuring equipment is recommended.

The suspension can be given using the measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight).

Thus for initiation of the therapy on the first day, twice the maintenance volume will be required. A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

Adverse reactions

Dogs:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Appetite loss, Lethargy

Vomiting, Diarrhoea, Blood in faeces¹, Haemorrhagic diarrhoea, Haematemesis, Gastric ulcer, Small intestine ulcer, Large intestine ulcer Elevated liver enzymes Renal failure.

¹occult

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.